Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS)

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access